Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in \textit{OPRM1}


\textbf{ABSTRACT}

\textbf{BACKGROUND:} No opioid receptor, mu 1 (\textit{OPRM1}) gene polymorphisms, including the functional single nucleotide polymorphism (SNP) rs1799971, have been conclusively associated with heroin/other opioid addiction, despite their biological plausibility. We used evidence of polymorphisms altering \textit{OPRM1} expression in normal human brain tissue to nominate and then test associations with heroin addiction.

\textbf{METHODS:} We tested 103 \textit{OPRM1} SNPs for association with \textit{OPRM1} messenger RNA expression in prefrontal cortex from 224 European Americans and African Americans of the BrainCloud cohort. We then tested the 16 putative cis-expression quantitative trait loci (cis-eQTL) SNPs for association with heroin addiction in the Urban Health Study and two replication cohorts, totaling 16,729 European Americans, African Americans, and Australians of European ancestry.

\textbf{RESULTS:} Four putative cis-eQTL SNPs were significantly associated with heroin addiction in the Urban Health Study (smallest \(p = 8.9 \times 10^{-5}\)): rs9478495, rs3778150, rs9384169, and rs562859. Rs3778150, located in \textit{OPRM1} intron 1, was significantly replicated (\(p = 6.3 \times 10^{-5}\)). Meta-analysis across all case-control cohorts resulted in \(p = 4.3 \times 10^{-6}\); the rs3778150-C allele (frequency = 16\%–19\%) was associated with increased heroin addiction risk. Importantly, the functional SNP allele rs1799971-A was associated with heroin addiction only in the presence of rs3778150-C (\(p = 1.48 \times 10^{-6}\) for rs1799971-A/rs3778150-C and \(p = 0.79\) for rs1799971-A/rs3778150-T haplotypes). Lastly, replication was observed for six other intron 1 SNPs that had prior suggestive associations with heroin addiction (smallest \(p = 2.7 \times 10^{-6}\) for rs3823010).

\textbf{CONCLUSIONS:} Our findings show that common \textit{OPRM1} intron 1 SNPs have replicable associations with heroin addiction. The haplotype structure of rs3778150 and nearby SNPs may underlie the inconsistent associations between rs1799971 and heroin addiction.

\textbf{Keywords:} Genetic association study, Heroin, Multiancestry, Opioid, OPRM1, Prefrontal cortex

http://dx.doi.org/10.1016/j.biopsych.2015.01.003
expression of the receptor (21–25). However, rs1799971 associations with heroin and other drug addictions (13–17) have been modest and often inconsistent. Additional OPRM1 single nucleotide polymorphisms (SNPs) have been tested for association with heroin/opioid addiction (10,12,13,18,19), but none of the findings have been independently replicated.

To enhance the detection of replicable OPRM1 SNP associations with heroin addiction, our study focused only on SNPs with evidence for altering OPRM1 messenger RNA expression in human brain, thereby reducing the multiple testing burden with a limited number of plausible regulatory SNPs carried forward for disease association testing. This approach was motivated by prior findings that psychiatric and other disease-associated SNPs tag expression quantitative trait loci (eQTL) more often than unassociated SNPs (26–28). Other studies have successfully used cis-eQTL mapping to nominate SNPs and consequently find associations with complex diseases, such as Crohn’s disease (29), chronic obstructive pulmonary disease (30), and amyotrophic lateral sclerosis (31). We used cis-eQTL mapping to identify SNPs associated with OPRM1 messenger RNA expression in human prefrontal cortex from 224 BrainCloud cohort participants (32) who had no evidence of drug use/abuse at the time of death and tested the putative cis-eQTL SNPs for association with heroin addiction across three independent cohorts totaling 16,729 (4287 cases and 12,442 control subjects). Our findings revealed replicable and highly significant SNP associations with heroin addiction and provided strong support of OPRM1 as an important susceptibility gene for heroin addiction.

Cis-eQTL Mapping Using Human Prefrontal Cortex in the BrainCloud Cohort

To identify putative cis-eQTL SNPs for OPRM1, we utilized SNP genotype and gene expression data (Supplement 1) available on postmortem dorsolateral prefrontal cortex samples from 110 European Americans and 114 African Americans, ranging in age from 0 to 78 years old, who had no neuropathologic or neuropsychiatric diagnoses, no drug or alcohol abuse, and no positive toxicology result (32–34).

Normalized ratios of gene expression levels from the single OPRM1 probe available in BrainCloud (Figure S1 in Supplement 1) were log-transformed and tested for association with additive three-level SNP genotypes using the BrainCloud software (32). Genotyped SNP association results were generated from the best fit general linear model with race, sex, age, life stage (infant, child, teen, and adult), and an age by life stage interaction included as the range of covariates. Inclusion of age, life stage, and the corresponding interaction was used to account for nonlinear trajectories of age-dependent gene expression over the life span (33). We evaluated associations overall and stratified by ancestry for the 103 SNPs genotyped across OPRM1 and its 100 kilobase flanking regions. A p value threshold of .00125, which takes into account the correlations among the 103 OPRM1 SNPs (α = .05/40 independent tests) (35,36), was used to declare statistical significance. Given the hypothesis-generating nature of our cis-eQTL mapping, SNPs associated with OPRM1 expression at the nominal significance threshold of p < .05 were carried forward for association testing with heroin addiction.

Discovery Cohort for Heroin Addiction Association Testing: Urban Health Study Cases versus Population Control Subjects

European American and African American cases were drawn from the Urban Health Study (UHS), one of the largest studies of street-recruited injection drug users in North America (37). See Supplement 1 for further details on the UHS design. Stored serum samples from 3227 UHS participants were selected for genotyping on the Illumina Omni1-Quad BeadChip (Illumina, Inc, San Diego, California) (38). Over 60% of the genotyped UHS participants met the Office of National Drug Control Policy definition of heroin abuse (injecting 10+ times in the past 30 days) (39,40), which is highly correlated with clinical levels of dependence on the Severity of Dependence Scale (41,42) and with DSM-IV (43) heroin abuse/dependence in analyses of the National Household Survey on Drug Use and Health data (87% positive predictive value; see Supplemental Methods and Table S1 in Supplement 1). These UHS participants, who abused heroin an average of 80.9 times in the past month and were very likely dependent on it, are henceforth referred to as heroin addiction cases. The remaining genotyped UHS participants who were addicted to cocaine or other substances but not addicted to heroin were not included in the current study.

For comparison with the UHS heroin addiction cases, we used six study cohorts from the database of Genotypes and Phenotypes (dbGaP) as a source of control subjects. Several prior studies have been reliably conducted using a similar design with study cases and population control subjects (44–49). See Supplemental Methods, Table S2, and Figure S2 in

METHODS AND MATERIALS

Figure 1 outlines our overall study design of conducting cis-eQTL mapping for OPRM1 in nonaddicted BrainCloud participants and testing the nominated SNPs for association in heroin addiction case-control cohorts. All study protocols received Institutional Review Board approval at their respective sites, and all study participants or their legal next of kin provided informed consent.

Figure 1. Overview of study design. CIDR, Center for Inherited Disease Research; eQTL, expression quantitative trait loci; mRNA, messenger RNA; SNP, single nucleotide polymorphism.
Supplement 1 for an outline of our cohort selection and quality control processes. There were no apparent biases underlying our control dataset, as indicated by genomic control inflation factor ($\hat{\lambda}_{GC} \leq 1.05$ for all pairwise combinations of dbGaP cohorts (Tables S3 and S4 in Supplement 1). Our final analysis dataset included 7095 European Americans (711 UHS heroin addiction cases and 6384 population control subjects) and 3662 African Americans (1293 UHS heroin addiction cases and 2369 population control subjects).

To capture all of the nominated cis-eQTL SNPs, genotype imputation was conducted using IMPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) (50) with reference to all 1000 Genomes haplotype panels (http://www.1000genomes.org/) (51,52). To avoid potential bias due to UHS cases and population control subjects being genotyped on different arrays, imputations were based on the intersection of SNPs available across all participants (53). Further details on quality control and imputation are provided in Supplement 1.

Replication Cohorts for Heroin Addiction Association Testing

Two independent cohorts, comprised of heroin and other opioid abuse/dependent participants (henceforth referred to as heroin addiction cases) and their own control subjects, were used to replicate SNP associations with heroin addiction. First, we used African Americans from the “Alcohol Dependence GWAS in European- and African-Americans (CIFDR-Gelernter Study)” (dbGaP accession number phs000425.v1.p1) (7). Our final analysis dataset included 852 African Americans (307 DSM-IV defined cases of heroin/other opioid abuse or dependence and 545 control subjects with no illicit drug abuse or dependence; Supplemental Methods and Table S2 in Supplement 1). European Americans from this cohort were not analyzed because there was an insufficient number of independent control subjects (<5) who met our inclusion criteria.

Second, we used DSM-IV defined cases of heroin dependence and general population control subjects gathered from Australian datasets, many of which are deposited in dbGaP (accession number phs000277.v1.p1). We henceforth refer to them as the Australian Heroin Dependence Study. A subset of this case-control cohort and descriptions of the study design have been previously described (10). Our final analysis dataset totaled 5120 Australians of European ancestry (1976 cases and 3144 control subjects; Supplemental Methods and Table S2 in Supplement 1).

Statistical Analyses: Association Testing with Heroin Addiction

Putative cis-eQTL SNPs were tested for association with heroin addiction across both ancestry groups in the discovery cohort (UHS vs. population control subjects). Significantly associated SNPs were then tested for replication in the CIDR-Gelernter Study and the Australian Heroin Dependence Study. Observed SNP genotypes or imputed SNP genotype dosages were tested for association using logistic regression models, separately by cohort and by ancestry group, with adjustment for sex and principal component eigenvectors (Supplement 1). SNP association results were compared using the Forest Plot Viewer (http://ntp.niehs.nih.gov/help/browsers/metadata/index-2.html) (54) and combined via fixed-effects sample size weighted meta-analyses, as used in prior multiancestry meta-analyses (55,56). As shown in Figure 1, at each stage of the association testing, linkage disequilibrium among the tested SNPs was taken into account to compute the p value thresholds for declaring statistical significance (35,36) ($\alpha = .05$/number of independent tests): meta-analysis $p < .0050$ based on 10 independent tests in the discovery stage and meta-analysis $p < .0125$ based on 4 independent tests in the replication stage.

Bioinformatic Analyses

Linkage disequilibrium patterns were discerned using LocusZoom (http://csg.sph.umich.edu/locuszoom/) (57) and Haploview (http://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haplovieview/haploview) (58) with reference to two 1000 Genomes panels: EUR (comprised of European Americans, Finns, Britons, Spaniards, and Italians) and AFR (comprised of African Americans, Kenyans, and Nigerians). SNPs were annotated according to their location in the longest principal isoform for OPRM1, according to the APPRIS database (http://appris.bioinfo.cnio.es) (59). Regulatory SNP annotations were taken from the HaploReg v2 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) database containing information on chromatin states, conservation, and regulatory motif alterations from the Encyclopedia of DNA Elements and elsewhere (60).

RESULTS

Cis-eQTL Mapping in Human Prefrontal Cortex

Sixteen of the 103 SNPs tested for association with OPRM1 expression in the BrainCloud cohort were nominated as cis-eQTL SNPs (Figure 1; Table 1): 9 SNPs overall, 2 SNPs when analyzing only European Americans, and 5 SNPs when analyzing only African Americans. Three of the cis-eQTL SNPs were significantly associated with OPRM1 expression at $p < .00125$, based on an overall $\alpha = .05$ corrected for 40 independent tests among the 103 OPRM1 SNPs (35,36); the other 13 SNPs were nominally associated at $p < .05$. Results of all tested SNPs are shown in Table S5 in Supplement 1.

HaploReg v2 (60) corroborated the regulatory potential of the putative cis-eQTL SNPs, showing that almost all of them are predicted to alter one or more of the regulatory motifs indicative of transcription factor binding sites (61,62) (Table S6 in Supplement 1). Moreover, rs3778150 resides in a highly conserved region, and two of the SNPs (rs562859 and rs13203628) are located in DNase hypersensitivity and enhancer sites (Table S6 in Supplement 1).

Testing cis-eQTL SNPs for Association with Heroin Addiction

The 16 putative cis-eQTL SNPs for OPRM1 were tested for association with heroin addiction in UHS cases versus population control subjects (Figure 1; Table 1). There was no evidence to suggest heterogeneity for any of the 16 SNPs (smallest $p = .15$), and the imputation quality of all tested SNPs was high (info $\geq .9$). Meta-analysis across the ancestry groups revealed 4 SNPs significantly associated with heroin addiction at $p < .005$, based on an overall $\alpha = .05$ corrected for 10 independent tests among the 16 cis-eQTL SNPs (35,36);
Table 1. Sixteen Putative cis-eQTL SNPs for OPRM1 in the BrainCloud Cohort and Tested for Association with Heroin Addiction in European American and African American Cases from the Urban Health Study Versus Population Control Subjects

<table>
<thead>
<tr>
<th>SNP (Minor Allele)</th>
<th>Base Pair Position (NCBI Build 36)</th>
<th>SNPs Type (Distance to OPRM1 for Intergenic SNPs)</th>
<th>Association with OPRM1 Expression in BrainCloud</th>
<th>Association with Heroin Addiction</th>
<th>Meta-analysis p</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNP</td>
<td>Overall</td>
<td>European Americans Only (n = 110)</td>
<td>African Americans Only (n = 114)</td>
<td>MAF, p, OR (95% CI)</td>
<td>MAF, p, OR (95% CI)</td>
</tr>
<tr>
<td>rs9478495 (A)</td>
<td>154,365,602</td>
<td>intergenic (–36,533)</td>
<td>.22, .89, .015</td>
<td>.22, .019, 1.16 (1.02–1.30)</td>
<td>.16, .0017, 1.27 (1.09–1.47)</td>
</tr>
<tr>
<td>rs3778150 (C)</td>
<td>154,425,351</td>
<td>intronic</td>
<td>.089, .042, .38</td>
<td>.19, .037, 1.15 (1.01–1.30)</td>
<td>.16, .0012, 1.28 (1.10–1.47)</td>
</tr>
<tr>
<td>rs9384169 (C)</td>
<td>154,354,864</td>
<td>intergenic (–47,271)</td>
<td>.25, .90, .046</td>
<td>.31, .029, 1.12 (1.01–1.25)</td>
<td>.32, .025, 1.15 (1.02–1.30)</td>
</tr>
<tr>
<td>rs562659 (C)</td>
<td>154,456,266</td>
<td>synonymous</td>
<td>.054, .016, .96</td>
<td>.38, .018, 1.13 (1.02–1.25)</td>
<td>.33, .070, 1.12 (99–126)</td>
</tr>
<tr>
<td>rs613355 (C)</td>
<td>154,491,542</td>
<td>intronic</td>
<td>.010, .012, .72</td>
<td>.39, .071, 1.10 (99–1.22)</td>
<td>.34, .067, 1.12 (99–1.26)</td>
</tr>
<tr>
<td>rs13203628 (G)</td>
<td>154,502,815</td>
<td>intronic</td>
<td>.037, .010, .82</td>
<td>.34, .068, 1.11 (99–1.23)</td>
<td>.26, .11, 1.11 (97–1.28)</td>
</tr>
<tr>
<td>rs671531 (A)</td>
<td>154,482,434</td>
<td>intronic</td>
<td>.015, .010, .92</td>
<td>.39, .11, 1.08 (98–1.20)</td>
<td>.33, .079, 1.11 (99–1.26)</td>
</tr>
<tr>
<td>rs9479779 (G)</td>
<td>154,544,688</td>
<td>intronic</td>
<td>.30, .57, .042</td>
<td>.085, .57, 1.05 (88–1.25)</td>
<td>.059, .20, .84 (65–1.10)</td>
</tr>
<tr>
<td>rs558948 (T)</td>
<td>154,483,556</td>
<td>intronic</td>
<td>.0017, .00094, .71</td>
<td>.16, .76, 1.02 (89–1.16)</td>
<td>.25, .58, 1.04 (91–1.19)</td>
</tr>
<tr>
<td>rs650825 (A)</td>
<td>154,470,229</td>
<td>intronic</td>
<td>.0034, .0017, .45</td>
<td>.17, .86, .99 (87–1.12)</td>
<td>.25, .57, 1.04 (91–1.19)</td>
</tr>
<tr>
<td>rs10485060 (A)</td>
<td>154,557,793</td>
<td>intronic</td>
<td>.039, .34, .24</td>
<td>.022, .23, .81 (57–1.15)</td>
<td>.047, .66, 1.06 (81–1.39)</td>
</tr>
<tr>
<td>rs647192 (G)</td>
<td>154,464,437</td>
<td>intronic</td>
<td>.0085, .0018, .63</td>
<td>.085, .80, .98 (82–1.17)</td>
<td>.25, .60, 1.04 (91–1.18)</td>
</tr>
<tr>
<td>rs647303 (C)</td>
<td>154,324,902</td>
<td>intergenic (–77,233)</td>
<td>.79, .28, .0010</td>
<td>.11, .29, 1.09 (93–1.27)</td>
<td>.26, .60, .97 (85–1.10)</td>
</tr>
<tr>
<td>rs6900805 (G)</td>
<td>154,329,725</td>
<td>intergenic (–72,410)</td>
<td>.79, .28, .0010</td>
<td>.11, .34, 1.08 (92–1.26)</td>
<td>.26, .63, .97 (85–1.10)</td>
</tr>
<tr>
<td>rs538174 (C)</td>
<td>154,494,229</td>
<td>intronic</td>
<td>.012, .0028, 1.00</td>
<td>.076, .27, .89 (74–1.09)</td>
<td>.24, .35, 1.06 (93–1.22)</td>
</tr>
<tr>
<td>rs1582629 (T)</td>
<td>154,564,452</td>
<td>intronic</td>
<td>.044, .090, .38</td>
<td>.42, .96, 1.00 (90–1.10)</td>
<td>.43, .87, 1.01 (90–1.13)</td>
</tr>
</tbody>
</table>

SNPs are sorted by the meta-analysis p value for association with heroin addiction, with statistically significant results shown in bold (meta-analysis p < .005).

CI, confidence interval; eQTL, expression quantitative trait loci; MAF, minor allele frequency; NCBI, National Center for Biotechnology Information; OR, odds ratio; SNP, single nucleotide polymorphism.
rs9478495, rs3778150, rs9384169, and rs562859. Minor alleles of these four SNPs were common (frequencies ranging from 16% to 38%), and they had consistent directions of association: odds ratios ranging from 1.12 to 1.28 across the ancestry groups. The two most significantly associated SNPs for heroin addiction (rs9478495 and rs3778150) were in moderate linkage disequilibrium in the 1000 Genomes EUR panel ($r^2 = .48$; Figure S3A in Supplement 1) but weak linkage disequilibrium in the AFR panel ($r^2 = .04$; Figure S3B in Supplement 1).

The four SNPs significantly associated with heroin addiction in the discovery cohort were then tested in African Americans from the CIDR-Gelernter Study and Australians of European ancestry from the Australian Heroin Dependence Study (Figure 1). Results are presented in Table S7 in Supplement 1. The rs3778150 association with heroin addiction was significantly replicated at $p = 6.8 \times 10^{-5}$, well below the corrected replication threshold $p < .0125$, based on an overall alpha $.05$ corrected for four independent tests (35,36). Meta-analysis of rs3778150 combining discovery and replication cohorts resulted in $p = 4.3 \times 10^{-8}$. As shown by the odds ratios estimates in Figure 2, the rs3778150 minor allele (C) was consistently associated with an increased heroin addiction risk in participants of European ancestry (1.28 in the UHS and 1.23 in the Australian Heroin Dependence Study) and African Americans (1.15 in the UHS and 1.20 in the CIDR-Gelernter Study), and it was associated at $p < .05$ in both UHS ancestry groups and the Australian heroin Dependence Study. The direction of the rs3778150-C association was consistent in the CIDR-Gelernter Study but with $p = .17$; this cohort was smaller than the others and thus had less statistical power than the rest of the cohorts. The three other tested SNPs were not replicated (Table S7 in Supplement 1).

The replicated SNP rs3778150 was originally implicated as a cis-eQTL SNP at $p = .042$ in BrainCloud European Americans (Table 1), the C allele being associated with reduced $OPRM1$ expression (Figure S4A in Supplement 1). Rs3778150 was not significantly implicated in the African Americans only ($p = .38$; Figure S4B in Supplement 1) or all BrainCloud participants ($p = .089$; Figure S4C in Supplement 1).

### Testing rs3778150–rs1799971 Haplotypes for Association with Heroin Addiction

We next evaluated linkage disequilibrium with the widely studied SNP rs1799971 ($r^2$ values shown in Figure S5 in Supplement 1 and D’ values shown in Figure S6 in Supplement 1). Rs3778150 and rs1799971 had $r^2 = 0$ and D’ = .5 in the AFR panel. In the EUR panel, rs3778150 and rs1799971 had D’ = 1; the rs3778150 minor allele (C, frequency = 15%) occurred on the same haplotype background with the rs1799971 major allele (A, frequency = 84%), but a weak $r^2$ value ($r^2 = .03$) reflected the discrepant allele frequencies.

Rs1799971 was not significantly associated with heroin addiction in any of the cohorts or ancestry groups individually or in a meta-analysis ($p = .12$), although its direction of association generally suggested that the major allele (A) conferred an increased risk with heroin addiction (Figure S7 in Supplement 1). Given the indication of a shared haplotype background between rs3778150 and rs1799971 in the EUR panel, we constructed the two SNP haplotypes and tested their associations with heroin addiction across all case-control cohorts and ancestry groups. As shown in Table 2, the haplotype carrying both the rs3778150-C and rs1799971-A alleles was consistently and significantly associated with increased risk of heroin addiction for each cohort and for both European Americans and African Americans: meta-analysis $p = 1.5 \times 10^{-5}$. The haplotype carrying rs1799971-A without rs3778150-C was not associated with heroin addiction in any of the cohorts or ancestry groups: meta-analysis $p = .79$.

### Testing Previously Implicated $OPRM1$ Intron 1 SNPs for Association with Heroin Addiction

Rs3778150 has varying linkage disequilibrium patterns with six other SNPs located in $OPRM1$ intron 1, which were previously reported for their associations with heroin/opioid addiction phenotypes (12,19) (Figures S8 and S9 in Supplement 1). The intron 1 location of these SNPs is designated according to the longest principal isoform for $OPRM1$ (59). Levran et al. (12) reported rs510769 and rs3778150 as having nominally signifi-

![Meta-analysis P=4.3x10^5](image-url)
cantly replicated at $p < .01$, whereas Zhang et al. (19) reported Rs524731 as having a nominally significant association with Rs511435, Rs3823010, and Rs495491 as having statistically significant associations that surpassed multiple testing correction. Nelson et al. (10), using a subset of the Australian replication cohort reported here, tested three of these SNPs (Rs510769, Rs3778151, and Rs496491) and found a nominal association for Rs3778151. To our knowledge, the six prior SNPs have not been tested elsewhere for independent replication. In a meta-analysis across all of our heroin addiction case-control cohorts, all six of the previously reported SNPs or their proxies were significantly replicated at $p < .01$ (overall $\alpha = .05$ corrected for five independent tests). Their meta-analysis $p$ values ranged from $7.0 \times 10^{-4}$ for Rs510769 to $2.7 \times 10^{-8}$ for Rs3823010 (Table 3). Similar to Rs3778150, the minor alleles were all associated with increased heroin addiction risk.

Rs3778150 and the top prior SNP Rs3823010 were in perfect linkage disequilibrium ($\lambda = 1$ and $\lambda' = 1$) with equivalent minor allele frequencies at 15% in EUR, and although $\lambda' = 1$ in AFR, their moderate $\lambda$ value of .54 reflected varied minor allele frequencies (20% for Rs3778150 and 12% for Rs3823010). In the African American cohorts from the current study where the SNPs were not collinear, both SNPs were associated with heroin addiction (African American specific meta-analysis $p = .013$ for Rs3778150 and $p = .0087$ for Rs3823010), but in follow-up regression analyses with both Rs3778150 and Rs3823010 included as predictors, neither SNP association remained (African American specific meta-analysis $p = .48$ for Rs3778150 and $p = .38$ for Rs3823010), suggesting that their associations with heroin addiction reflect the same underlying signal.

**DISCUSSION**

The focus of our study was to identify $OPRM1$ polymorphisms consistently associated with heroin addiction. To increase the likelihood of detecting such associations, we followed the strategy of mapping cis-eQTLs altering $OPRM1$ expression in human brain from nonaddicted participants, nominating this relatively small number of potentially regulatory polymorphisms and testing them for association with heroin addiction. Among 16 putative cis-eQTL SNPs, we found that Rs3778150 had a highly significant association with heroin addiction across three independent cohorts, even surpassing the standard genome-wide significance $p$ value threshold of $5 \times 10^{-8}$. Follow-up haplotype analyses showed that the widely studied missense SNP Rs1799971 was associated with heroin addiction only in the presence of the rs3778150 risk allele, suggesting that rs3778150 and its nearby correlated SNPs may explain the inconsistent associations of rs1799971 observed across numerous studies of heroin/opioid addiction.

The rs3778150 minor allele (C) was associated with both reduced $OPRM1$ expression and increased risk of heroin addiction, with its associations being strongest with European ancestry. It is common for cis-eQTL and disease risk associations to differ by ancestry, possibly due to unmeasured genetic or environmental modifiers (63). The direction of association between $OPRM1$ expression and risk of heroin addiction has not been conclusively shown. Nonetheless, our observed patterns for the rs3778150 minor allele are consistent

<table>
<thead>
<tr>
<th>Table 2. Haplotype Analyses of rs3778150 and the Widely Studied Missense SNP rs1799971 Across All Study Cohorts and Ancestry Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allele</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>C</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>G</td>
</tr>
<tr>
<td>A</td>
</tr>
</tbody>
</table>

The single SNP analyses suggested that the rs3778150 minor allele (C) and rs1799971 major allele (A) conferred increased risks for heroin addiction.
Table 3. Associations of Previously Implicated OPRM1 Intron 1 SNPs with Heroin Addiction Across the Cohorts Used in the Current Study (Urban Health Study, CIDR–Gelernter Study, and the Australian Heroin Dependence Study)

<table>
<thead>
<tr>
<th>SNP (Minor Allele)</th>
<th>Ref.</th>
<th>Previously Reported p</th>
<th>MAF</th>
<th>p</th>
<th>OR (95% CI)</th>
<th>Ref.</th>
<th>MAF</th>
<th>p</th>
<th>OR (95% CI)</th>
<th>Ref.</th>
<th>MAF</th>
<th>p</th>
<th>OR (95% CI)</th>
<th>Meta-analysis p</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3823010 (A)</td>
<td>(19)</td>
<td>.001</td>
<td>.12</td>
<td>.025</td>
<td>1.19 (1.02–1.37)</td>
<td>.16</td>
<td>8.6 × 10^{-4}</td>
<td>1.28 (1.11–1.49)</td>
<td>.13</td>
<td>.17</td>
<td>1.25 (0.91–1.72)</td>
<td>.17</td>
<td>2.4 × 10^{-4}</td>
<td>1.23 (1.10–1.37)</td>
</tr>
<tr>
<td>rs3778151 (C)</td>
<td>(10,12)</td>
<td>.003 (12)</td>
<td>.29</td>
<td>.029</td>
<td>1.12 (1.01–1.27)</td>
<td>.16</td>
<td>3.0 × 10^{-3}</td>
<td>1.25 (1.08–1.45)</td>
<td>.31</td>
<td>.33</td>
<td>1.12 (0.98–1.28)</td>
<td>.17</td>
<td>3.2 × 10^{-4}</td>
<td>1.23 (1.10–1.37)</td>
</tr>
<tr>
<td>rs524731 (A)</td>
<td>(19)</td>
<td>.011</td>
<td>.12</td>
<td>.065</td>
<td>1.15 (0.99–1.33)</td>
<td>.21</td>
<td>1.4 × 10^{-3}</td>
<td>1.25 (1.09–1.43)</td>
<td>.12</td>
<td>.17</td>
<td>1.25 (0.91–1.75)</td>
<td>.21</td>
<td>3.7 × 10^{-3}</td>
<td>1.16 (0.95–1.32)</td>
</tr>
<tr>
<td>rs511435 (T)</td>
<td>(19)</td>
<td>.002</td>
<td>.20</td>
<td>.15</td>
<td>1.10 (0.97–1.23)</td>
<td>.21</td>
<td>1.4 × 10^{-3}</td>
<td>1.25 (1.09–1.43)</td>
<td>.19</td>
<td>.17</td>
<td>1.20 (0.93–1.59)</td>
<td>.21</td>
<td>3.7 × 10^{-3}</td>
<td>1.16 (0.95–1.32)</td>
</tr>
<tr>
<td>rs495491 (G)^a</td>
<td>(19)</td>
<td>.002</td>
<td>.52</td>
<td>.015</td>
<td>1.14 (1.02–1.29)</td>
<td>.26</td>
<td>8.2 × 10^{-3}</td>
<td>1.19 (1.04–1.35)</td>
<td>.52</td>
<td>.25</td>
<td>1.14 (0.91–1.43)</td>
<td>.26</td>
<td>8.4 × 10^{-3}</td>
<td>1.14 (0.93–1.38)</td>
</tr>
<tr>
<td>rs510769 (T)</td>
<td>(12)</td>
<td>.0008</td>
<td>.24</td>
<td>.97</td>
<td>1.00 (0.89–1.12)</td>
<td>.26</td>
<td>1.0 × 10^{-2}</td>
<td>1.19 (1.04–1.35)</td>
<td>.24</td>
<td>.29</td>
<td>1.15 (0.88–1.52)</td>
<td>.26</td>
<td>8.4 × 10^{-3}</td>
<td>1.14 (0.93–1.38)</td>
</tr>
</tbody>
</table>

These SNPs were reported for having nominally to statistically significant associations with heroin addiction (n = 412 cases and 184 control subjects, comprised of European Americans or Israelis with Jewish ancestry) (12), opioid dependence (n = 91 cases and 338 control subjects, comprised of all European Americans) (19), or heroin dependence (n = 1459 cases and 531 control subjects, comprised of Australians of European ancestry) (10). None of these SNPs were previously tested for independent replication. SNPs are sorted by meta-analysis p value.

CI, confidence interval; CIDR, Center for Inherited Disease Research; EUR, 1000 Genomes panel comprised of European Americans, Finns, Britons, Spaniards, and Italians; GWAS, genome-wide association study; MAF, minor allele frequency; OR, odds ratio; Ref., reference; SNP, single nucleotide polymorphism.

^These SNPs were not available as genotyped SNPs in the Heroin Dependence GWAS, so the following SNPs in high linkage disequilibrium were used: rs514980 as a proxy SNP for both rs511435 and rs524731 (r^2 = 1 and D' = 1 in 1000 Genomes EUR) and rs3778153 as a proxy SNP for rs3778151 (r^2 = .98 and D' = 1 in 1000 Genomes EUR). The best proxy for rs495491 was the other previously reported SNP rs510769 (r^2 = .98 and D' = 1 in 1000 Genomes EUR).

^For rs495491, G is the minor allele in populations of European ancestry, but A is the minor allele in African Americans. The presented allele frequencies correspond to the G allele.

^Meta-analysis was computed using the results that were available.
with one prior report noting reduced OPRM1 expression levels in thalamus and secondary somatosensory cortex samples of heroin addicts compared with control subjects and postulating that downregulation of OPRM1 may play a role in increasing risk of heroin addiction by disrupting the opioid system of a key compensatory response to heroin (25). More specifically, heroin exposure results in reduced μ receptor function, and in response, the opioid system upregulates OPRM1 expression to make more μ receptors available. It is plausible that genetic polymorphisms attenuating OPRM1 expression could help this compensatory mechanism, leading to a greater quantity of heroin being needed to trigger a physiological effect and thus increasing risk of becoming addicted to heroin.

One prior study reported a nominal association between rs3778150 and heroin dependence. Using a subset of the Australian Heroin Dependence Study reported here (n = 1459 cases and 531 general population control subjects), Nelson et al. (10) found that rs3778150 was associated with DSM-IV defined heroin dependence at \( p = 0.024 \), but this finding did not pass multiple testing correction in that study. The rs3778150 association signal was greatly strengthened with the larger sample size in this study; \( p = 1.7 \times 10^{-8} \) in the Australian Heroin Dependence Study (\( n = 5120 \)) and meta-analysis \( p = 4.3 \times 10^{-8} \) across all cohorts (total \( n = 16,729 \)). Beyond rs3778150, six other OPRM1 intron 1 SNPs have been reported for their associations with heroin or other opioid addiction phenotypes. Levran et al. (12) reported that rs510769 and rs3778151 were nominally associated in 596 European American severe heroin addicts and healthy control subjects, but these findings did not surpass multiple testing correction. Zhang et al. (19) found that rs524731, rs511435, rs3823010, and rs495491 were nominally to significantly associated in 429 European American DSM-defined opioid dependent cases and control subjects, who were ascertainment in parallel with the African Americans from the CIDI–Gelernter Study that we included in our study. We tested the prior SNPs or their proxies across the cohorts used in the current study and found statistically significant evidence to support their associations (smallest meta-analysis \( p = 2.7 \times 10^{-8} \) for rs3823010; Table 3). Rs3823010 was not associated with OPRM1 expression (smallest \( p = 0.12 \); Table S5 in Supplement 1). Nonetheless, the directions of association for the previously reported SNPs were consistent with our rs3778150 finding; the minor alleles being associated with increased risk. The regulatory potentials of the prior SNPs were hypothesized given their positions in a noncoding region (12,19,64).

Our findings show, for the first time, that OPRM1 intron 1 contains SNPs that have replicable associations with heroin addiction. Our findings further suggest that rs3778150 and possibly other intron 1 SNPs may tag a cis-eQTL that influences OPRM1 expression and underlies the disease associations. Our tested SNPs also included rs563649, which is located in intron 1 and was previously reported for being associated with OPRM1 expression in vitro (65); we did not corroborate this association with OPRM1 expression (smallest \( p = .26 \); Table S5 in Supplement 1) and did not find evidence for association with heroin addiction in our discovery cohort (meta-analysis \( p = .57 \)). Fine-mapping in the intron 1 region, particularly in diverse ancestry groups with varied linkage disequilibrium patterns, is needed to delineate the variants that influence both OPRM1 expression and heroin addiction.

Our findings were made possible by mapping putative cis-eQTL SNPs in prefrontal cortex, a highly relevant brain region when studying addiction and other psychiatric diseases (65). The prefrontal cortex is the center for mammalian purposive action including self-control/response inhibition, emotional regulation, flexibility/control of attention, and planning and goal formation. Dysregulation of this region can increase impulsivity and risk taking and stress reactivity and bias attention and reward anticipation toward immediate rather than delayed gratification, all characteristics associated with greater risk of addiction (66). Differences in prefrontal cortex activity have been observed in numerous human brain imaging studies comparing healthy control subjects with those with heroin/opioid or other drug addictions (66).

Limitations of our study include reliance on SNP genotyping and gene expression microarrays for the cis-eQTL mapping means that structural or rare genetic variants were not captured, coverage of common genetic variants was more complete for the participants of European ancestry compared with the African Americans, and only a single OPRM1 probe was represented. Future studies capturing more complete genetic variation and more localized expression patterns and measuring other brain regions relevant to addiction (67) may lead to the identification of other important regulatory polymorphisms associated with heroin addiction.

When testing the putative cis-eQTL SNPs for association with heroin addiction, many of the cases used in our study were derived from the UHS, where no study control subjects were available, and they were compared with a set of population control subjects obtained via dbGap. This study design enabled us to create a large sample size for heroin addiction association testing. Stringent quality control was implemented to reduce the chances of introducing artificial biases, and our top findings were corroborated in independent cohorts including DSM-IV assessed cases and study control subjects. Greater power for identifying variants associated specifically with heroin addiction could be achieved with a large sample of control subjects who had used heroin but never became addicted. No such large sample of exposed but never addicted control subjects exists, but their absence does not diminish the observed associations of rs3778150 and other intron 1 SNPs with heroin addiction.

A more complete understanding of the biological factors that underlie the risk of developing heroin addiction is needed to combat its high prevalence and societal impact. To date, no specific genetic variants have been conclusively identified despite much research focused on OPRM1 and its missense SNP rs1799971. Our hypothesis-generating approach of converging cis-eQTL mapping and SNP-disease association testing led to the identification of minor alleles at two OPRM1 intron 1 SNPs (rs3778150 and rs3823010) that are consistently associated with increased risk of heroin addiction across independent cohorts with \( p \) values that even exceed the stringent genome-wide significance threshold (\( p < 5 \times 10^{-8} \)). Our findings highlight the importance of OPRM1 intron 1 and its underlying haplotype structure that provides an explanation for the widely studied but largely inconsistent association observed for rs1799971, giving credence to the prior suggestion that haplotypes carrying noncoding regulatory SNPs may explain the rs1799971 inconsistencies (19,64). Consideration of
OPRM1 Associations with Heroin addiction

these intrinsic SNPs and their regulatory effects on OPRM1 expression in disease-relevant human brain tissues is needed to better understand the role of OPRM1 in influencing risk of heroin and other addictions.

ACKNOWLEDGMENTS AND DISCLOSURES

The BrainCloud dataset used for the expression quantitative trait loci mapping described in this article was obtained from database of Genotypes and Phenotypes (dbGaP) (http://www.ncbi.nlm.nih.gov/gap) via accession number phs000417.v1.p1. Submission of the data to dbGaP was provided by Drs. Barbara Lipska and Joel Kleinman. Collection of the data was through a collaborative study sponsored by the National Institute of Mental Health Intramural Research Program. The BrainCloud applications were downloaded from http://braincloud.jhmi.edu.

This genetic study of heroin addiction cases from the Urban Health Study was supported by the National Institute of Drug Abuse Grant numbers R33 DA027486 and R01 DA026141. Genotyping was conducted at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University.

Control subjects used for comparison with the Urban Health Study cases were drawn from the following six cohorts in dbGaP.

1) Funding support for the Study of Addiction: Genetics and Environment was provided through the National Institutes of Health (NIH) Genes, Environment and Health Initiative (GEI) (U01 HG004422). The Study of Addiction: Genetics and Environment is one of the genome-wide association studies (GWAS) funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information (NCBI). Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392), and the Family Study of Cocaine Dependence (R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University CIDR, was provided by the NIH GEI (U01 HG004437), the National Institute on Alcohol Abuse and Alcoholism, National Institute of Drug Abuse, and the NIH contract “High Throughput Genotyping for Studying the Genetic Contributions to Human Disease” (HHSN268200720096C). The datasets used for the analyses described in this article were obtained via dbGaP accession number phs000092.v1.p1.

2) We acknowledge the contribution of data from “Genetic Architecture of Smoking and Smoking Cessation” accessed through dbGaP accession number phs000404.v1.p1. Funding support for genotyping, which was performed at CIDR, was provided by X01 HG005274. CIDR is fully funded through a federal contract from the NIH to The Johns Hopkins University CIDR, was provided by the NCBI. Support for collection of datasets and samples was provided by the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392) and the University of Wisconsin Transdisciplinary Tobacco Use Research Center (P50 DA019706 and P50 CA084724).

3) Funding support for the GWAS of Ischemic Stroke study was provided through the NIH GEI (U01 HG004436). The GWAS of Ischemic Stroke Study is one of the GWAS funded as part of GENEVA under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the NCBI. Funding support for genotyping, which was performed at The Johns Hopkins University CIDR, was provided by the NIH GEI (U01HG004438 and NIH contract number HHSN268200720096C). Field work for this project was supported by a Cooperative Agreement with the Division of Adult and Community Health, Centers for Disease Control and Prevention; the National Institute of Neurological Disorders and Stroke (NINDS) and the NIH Office of Research on Women’s Health (R01 NS45012); Office of Research and Development, Medical Research Service, Department of Veterans Affairs; and the University of Maryland General Clinical Research Center (M01 RR165001). National Center for Research Resources, NIH. This study used samples from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds). The datasets used for the analyses described in this article were obtained via dbGaP accession number phs000292.v1.p1.

4) Funding support for the GENEVA Prostate Cancer study was provided through the National Cancer Institute (R37 CA54281, R01 CA63464, P01 CA33619, U01 CA136792, U01 CA98758, and RC2 CA148085) and the National Human Genome Research Institute (U01 HG004726), Assistance with phenotype harmonization, single nucleotide polymorphism selection, data cleaning, meta-analyses, data management and dissemination, and general study coordination was provided by the GENEVA Coordinating Center (U01 HG004789). The datasets used for the analyses described in this article were obtained from dbGaP at phs000306.v2.p1.

5) This work utilized, in part, data from the NINDS dbGaP database from the CIDR NeuroGenetics Research Consortium Parkinson’s disease study (accession number phs000196.v2.p1).

6) For the “High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes Investigation,” research support to collect data and develop an application to support this project was provided by P05 CA093459, P50 CA097007, R01 ES011740, and R01 CA133996 (dbGaP accession number phs000187.v1.p1).

Two additional cohorts with heroin addiction cases and control subjects were used for replication testing. For the first replication cohort, funding support was provided through the Center for Inherited Disease Research and the Genetics of Alcohol Dependence in American Populations. This CIDR-Gelernter Study is a GWAS funded as part of the “Genetics of Alcohol Dependence in American Populations” cohort, and its investigators provided assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination. Assistance with data cleaning was provided by the NCBI. Support for collection of datasets and samples was provided by the National Institute on Alcohol Abuse and Alcoholism Grant number R01 AA011330. Funding support for genotyping, which was performed at the Johns Hopkins University CIDR, was provided by the NIH GEI (U01 HG004438), the NIAAA, and the NIH contract number HHSN268200720096C. The datasets used for the analyses described in this article were obtained via dbGaP accession number phs000425.v1.p1.

The second replication cohort included cases who met lifetime DSM-V criteria for heroin dependence compared with general population control subjects. Cases and control subjects, many of which are available in dbGaP under “A Genome-Wide Association Study of Heroin Dependence” (accession number phs000277.v1.p1), were derived from the following datasets: 1) The Comorbidity and Trauma Study was funded by National Institute on Alcohol Abuse and Alcoholism Grant number R01 DA17305; 2) The Western Australia Study on Heroin Dependence was funded by the Australia Government’s National Health and Medical Research Council (Grant number 513962); 3) The Twin Study of Mole Development in Adolescence (principal investigator [PI]: Nick Martin) was funded by the Australian Government’s National Health and Medical Research Council (Grant number 389891); and 4) Support for the Hunter Community Study has been previously described (68). Lastly, GWAS genotyping services for “A Genome-Wide Association Study of Heroin Dependence” at CIDR, located at The Johns Hopkins University, were supported by NIH contract number N01 HG65403.

Financial support for this study was provided by the following Grants and contracts by the National Institutes of Health, an agency of the United States Department of Health and Human Services: R33 DA027486 (PI: EOJ), R01 DA26141 (PI: EOJ), R01 DA026911 (PI:NL5), U01 HG004422, U01 HG004446, U01 AA008401, P01 CA089392 (PI: LJLB), R01 DA013423 (PI: LJLB), R01 DA019963 (PI: LJLB), R01 DA025888 (Co-PIs: LJLB and EOJ), R01 DA036583 (PI: LJLB), U01 HG004436, HHSN268200720096C, R01 HG004726, P50 CA093459, U01 HG004438, R01 NS45012, R01 RR165001, R01 CA54281, R01 CA63464, P01 CA33619, R01 CA136792, U01 CA98758, RC2 CA148085, U01 HG004726, R01 HG004789, P50 CA093459, P50 CA097007, R01 ES011740, R01...
CA133996, R01 AA011330, R01 DA17305 (Pt: ECN), and N01-HG-65403. This study was also supported by the Australia Government’s National Health and Medical Research Council (Grant number 513862 with Pt: SGS and fellowship number 1041742 with Pt: LD), National Health and Medical Research Council (Grant number 389891 (Pt: NGM), and National Drug and Alcohol Research Centre, which was supported by funding from the Australian Government under the Substance Misuse and Service Improvements Grants Fund.

LJB and the spouse of NLS are listed as inventors on Issued U.S. Patent 8,080,371, “Markers for Addiction,” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. The remaining authors report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Behavioral Health Epidemiology Program, Behavioral Health and Criminal Justice Division (DBH, CQ), Research Triangle Institute (RTI) International; and Computing Division (JLL, CCN3), RTI International, Research Triangle Park, North Carolina; Department of Genetics (NLS), Washington University in St. Louis, St. Louis, Missouri; Center for Genomics in Public Health and Medicine (GPP), RTI International, Atlanta, Georgia; School of Psychiatry and Clinical Neurosciences (OKH, DW, EAK), University of Western Australia, Crawley, Western Australia, Australia; Department of Psychiatry and Psychotherapy (SGS), University of Erlangen-Nuremberg, Erlangen, Germany; Faculty of Science, Medicine, and Health (SGS), University of Wollongong, Wollongong, New South Wales; National Drug and Alcohol Research Centre (LD), University of New South Wales, Sydney; Queensland Institute of Medical Research Berghofer Medical Research Institute (NGM, GWM), Brisbane, Queensland; Centre for Clinical Epidemiology and Biostatistics (JA, EGH, MM), School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales; Clinical Research Design (JA, EGH), IT and Statistical Support Unit; Public Health Research Program (MM); and Center for Bioinformatics (RJS), Biomarker Discovery and Information-Based Medicine, Hunter Medical Research Institute, Newcastle, New South Wales; School of Biomedical Sciences and Pharmacy (RJS), University of Newcastle, Newcastle, New South Wales; and Division of Genetics (RJS), Hunter Area Pathology Service, Newcastle, New South Wales, Australia; Department of Psychiatry (LJB, ECN), Washington University School of Medicine, St. Louis, Missouri; Urban Health Program (AK), Behavioral Health and Criminal Justice Division, RTI International, San Francisco, California; and Fellow Program and Behavioral Health and Criminal Justice Division (EOJ), RTI International, Research Triangle Park, North Carolina.

Address correspondence to Dana B. Hancock, Ph.D., Behavioral Health Epidemiology Program, RTI International, 3040 East Cornwallis Road, PO Box 12194, Research Triangle Park, NC 27709; E-mail: dhancock@rti.org.

Received Oct 13, 2014; revised Dec 18, 2014; accepted Jan 8, 2015.

Supplementary material cited in this article is available online at http://dx.doi.org/10.1016/j.biopsych.2015.01.003.

REFERENCES


OPRM1 Associations with Heroin addiction


